GlassScriptPhysician profile
Colin Knue
NPI 1902448525
$399.53
in general payments reported to CMS, 2019-2025
12 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.27 · 2022: $35.32 · 2023: $65.96 · 2024: $147 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $82.59 | 2021-2022 | |
| Ucb, INC. | $76.37 | 2024-2025 | Briviact |
| Merck Sharp & Dohme LLC | $45.31 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Paratek Pharmaceuticals, INC. | $38.86 | 2025 | Nuzyra |
| Boston Scientific Corporation | $35.05 | 2024-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $20.75 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.84 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $18.50 | 2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.06 | 2023 | Spiriva Respimat, Stiolto Respimat |
| La Jolla Pharmaceutical Company | $15.55 | 2024 | Xerava |
| Pfizer INC. | $15.11 | 2024 | |
| Abiomed | $14.54 | 2023 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Knue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.